Literature DB >> 29905765

Pleural mesothelioma: is the surgeon still there?

I Opitz1, W Weder2.   

Abstract

Malignant pleural mesothelioma (MPM) is a rare malignancy with some unique characteristics. Tumor biology is aggressive and prognosis is poor. Despite more knowledge on histology, tumor biology and staging, there is still a relevant discrepancy between clinical and pathologic staging resulting in difficult prediction of prognosis and treatment outcome, making treatment allocation more challenging than in most other malignancies. After years of nihilism in the late 80s, a period of activism started evaluating different treatment protocols combined with research driven mainly by academic centers; at the time, selection was based on histology and stage only. This period was important to gain knowledge about the disease. However, the interpretation of data was difficult since selection criteria and definitions varied substantially. Not surprisingly, until now there is no common agreement on best treatment even among specialists. Hence, a review of our current concepts is indicated and personalized treatment should become applicable in the future. Surgery was and still is an issue of debate. In principle, surgery is an effective approach as it allows macroscopic complete elimination of a tumor, which is relatively resistant to medical treatment. It helps to set the clock back and other therapies that have also just a limited effect can be applied sequentially before or after surgery. Furthermore, to date best long-term outcome is reported from surgical series in combination with other modalities. However, part of the community considers surgery associated with too high morbidity and mortality when balanced to the limited life expectancy. This criticism is understandable, since poor results after surgery are reported. The present article will review the indication for surgery and discuss the different procedures available for macroscopic complete resection-such as lung-preserving (extended) pleurectomy/decortication as well as extrapleural pneumonectomy to illustrate that 'The surgeon is still there!'

Entities:  

Mesh:

Year:  2018        PMID: 29905765     DOI: 10.1093/annonc/mdy195

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  4 in total

1.  Editorial: Emerging Therapies for Malignant Mesothelioma.

Authors:  Nico van Zandwijk; Glen Reid; Paul Baas
Journal:  Front Oncol       Date:  2020-06-12       Impact factor: 6.244

2.  Evidence for marked underutilization of insurance billing in malignant pleural mesothelioma in Finland.

Authors:  Paulus Torkki; Juuso Paajanen; Ville Kytö; Sanna Laaksonen; Jari Räsänen; Marjukka Myllärniemi; Ilkka Ilonen
Journal:  Thorac Cancer       Date:  2021-09-13       Impact factor: 3.500

Review 3.  Current Management and Future Perspective in Pleural Mesothelioma.

Authors:  Rajiv Shah; Laura V Klotz; Julia Glade
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

4.  Sarcopenia, Precardial Adipose Tissue and High Tumor Volume as Outcome Predictors in Surgically Treated Pleural Mesothelioma.

Authors:  Oliver Guido Verhoek; Lisa Jungblut; Olivia Lauk; Christian Blüthgen; Isabelle Opitz; Thomas Frauenfelder; Katharina Martini
Journal:  Diagnostics (Basel)       Date:  2022-01-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.